Comprehensive Guide to Alzheimer’s Treatment Options: Medications, Therapies, and Emerging Strategies

Key Takeaways

• Alzheimer’s disease remains incurable, but a range of treatments can alleviate symptoms and slow progression.
• Prescription drugs, experimental agents, and off‑label medications target memory loss and behavioral changes.
• Non‑pharmacologic approaches such as cognitive‑behavioral therapy, acupuncture, tailored diets, and light therapy can enhance quality of life.

Although a definitive cure for Alzheimer’s disease is not yet available, several FDA‑approved medications help manage cognitive decline and related symptoms. Ongoing research into experimental therapies and off‑label drug uses offers hope for future breakthroughs.

Both FDA‑approved agents and adjunctive treatments are categorized by their primary therapeutic goal—either improving cognition or addressing neuropsychiatric and functional symptoms.

FDA‑Approved Medications

Cholinesterase inhibitors increase acetylcholine, a neurotransmitter essential for memory and learning. In early‑ to moderate‑stage Alzheimer’s, they can modestly improve or stabilize cognition, although they do not halt disease progression.

For example, galantamine benefits roughly 14 % of patients (≈14 out of 100) in terms of thinking and memory.

Common cholinesterase inhibitors include:

• Donepezil (Aricept) – indicated for all stages of Alzheimer’s disease.
• Rivastigmine (Exelon) – approved for mild‑to‑moderate Alzheimer’s and Parkinson’s disease dementia.
• Galantamine (Razadyne) – approved for mild‑to‑moderate Alzheimer’s disease.

NMDA‑receptor antagonists, such as memantine (Namenda), regulate glutamate activity to protect neurons from excitotoxic damage. Memantine may improve memory, attention, and problem‑solving, and is often combined with a cholinesterase inhibitor for additive benefit.

Combination products merge a cholinesterase inhibitor with an NMDA antagonist to target multiple pathways simultaneously. Examples are:

• Memantine extended‑release + Donepezil (Namzaric)
• Rivastigmine transdermal patch (Exelon Patch)

A 2020 meta‑analysis found that memantine + donepezil produced greater gains in cognition, daily functioning, and neuropsychiatric symptoms than either drug alone or placebo.

Monoclonal Antibodies

Monoclonal antibodies are biologic agents designed to bind specific disease‑related proteins. They are administered intravenously or via injection.

Aducanumab (Aduhelm) targets amyloid‑beta plaques. The drug received accelerated FDA approval in 2021 despite mixed trial outcomes and ongoing debate about clinical benefit. It was discontinued in 2024 for strategic business reasons, not safety concerns.

Medications for Associated Symptoms

Antipsychotics may be prescribed for agitation, aggression, hallucinations, or delusions, but clinicians use them cautiously because of serious side‑effect risks. Frequently used agents include risperidone (Risperdal), olanzapine (Zyprexa), and quetiapine (Seroquel).

Antidepressants address depression and anxiety, common comorbidities in Alzheimer’s. Typical choices are sertraline (Zoloft), citalopram (Celexa), escitalopram (Lexapro), and fluoxetine (Prozac).

Anxiolytics such as lorazepam (Ativan), diazepam (Valium), alprazolam (Xanax), clonazepam (Klonopin), and buspirone (BuSpar) may relieve anxiety and restlessness, though they carry sedation and dependence risks.

Off‑Label Therapies Under Investigation

Metformin, a first‑line treatment for type 2 diabetes, is being studied for neuroprotective properties linked to improved insulin sensitivity, reduced oxidative stress, and lower inflammation—factors implicated in Alzheimer’s pathology.

Antihypertensive agents (ACE inhibitors, ARBs, calcium‑channel blockers, beta‑blockers) may mitigate vascular contributions to cognitive decline by controlling blood pressure and enhancing cerebral perfusion.

While pharmacologic options can be valuable, side effects such as severe sleep disturbances may limit tolerability. Complementary non‑pharmacologic interventions are essential for holistic care.

Non‑Pharmacologic Interventions

Cognitive‑behavioral therapy (CBT) targets maladaptive thoughts and behaviors. A 2023 meta‑analysis showed CBT significantly reduced depression scores in Alzheimer’s patients (38 %–50 % prevalence of depression).

Acupuncture aims to balance neurochemical activity and improve cerebral blood flow. A 2023 review suggested modest cognitive benefits and potential slowing of disease progression.

Exercise—both aerobic and resistance training—enhances memory, neuroplasticity, and reduces inflammatory markers. A 2023 systematic review linked regular activity with slower cognitive decline.

Dietary approaches that emphasize nutrient‑dense foods have demonstrated neuroprotective effects:

• Mediterranean diet – rich in fruits, vegetables, whole grains, nuts, and olive oil; reduces inflammation.
• DASH diet – focuses on fruits, vegetables, lean proteins, and low sodium to support blood‑pressure control.
• MIND diet – combines Mediterranean and DASH principles, emphasizing leafy greens and berries to protect brain health.
• Ketogenic diet – high‑fat, low‑carbohydrate regimen that supplies ketones as an alternative brain fuel, showing memory benefits in some trials.

Research consistently indicates that adherence to Mediterranean, DASH, or MIND patterns lowers Alzheimer’s risk, while the ketogenic diet may improve cognition across disease stages.

Transcranial near‑infrared (tNIR) light therapy demonstrated memory and verbal‑learning improvements in a 2021 study of 57 participants with mild‑to‑moderate dementia, alongside better sleep and mood.

Supplements frequently used by patients include:

• Omega‑3 fatty acids – anti‑inflammatory and membrane‑stabilizing.
• Ginkgo biloba – may enhance cerebral blood flow.
• Curcumin – antioxidant and anti‑inflammatory properties.
• Vitamin D – supports neuronal function.
• B‑vitamins – help lower homocysteine, a risk factor for cognitive decline.
• Probiotics – modulate the gut‑brain axis.

Before initiating any supplement, patients should consult a healthcare professional to avoid drug‑supplement interactions.

Emerging Pharmacologic Strategies

Current therapies primarily manage symptoms; they do not cure Alzheimer’s and can cause adverse effects. Consequently, researchers are developing multi‑target inhibitors that simultaneously address amyloid plaques, tau tangles, and neurotransmitter imbalances.

Advanced drug‑design platforms enable precise molecular modeling, accelerating the discovery of candidates that act on several disease pathways. Many of these agents remain in clinical trials, with several showing promising early‑phase results.

In summary, Alzheimer’s disease imposes a profound burden on patients and families. FDA‑approved drugs such as cholinesterase inhibitors and memantine provide modest symptomatic relief, while non‑pharmacologic measures—including CBT, exercise, diet, and acupuncture—can improve functional outcomes. Ongoing research into multi‑target agents and biologics holds promise for more effective disease management in the coming years.